BIOMAT Database Logo BIOMAT Database Logo

Rifabutine: minimal inhibitory and bactericidal concentrations for Mycobacterium tuberculosis. 1988

L B Heifets, and P J Lindholm-Levy, and M D Iseman
National Jewish Center for Immunology and Respiratory Medicine, Denver, CO 80206.

The minimal inhibitory concentrations (MIC) and minimal bactericidal concentrations (MBC) of rifabutine (ansamycin LM427, spiropiperidyl rifamycin) against rifampin-susceptible and rifampin-resistant strains of Mycobacterium tuberculosis were determined. The MICs for 17 rifampin-susceptible strains were low, falling in a narrow range of 0.06 microgram/ml or less when determined by either the agar-dilution method (in 7H10 or 7H11 agar) or in 7H12 broth (radiometrically or by sampling and colony-forming units [CFU/ml] determination). The MICs of rifabutine for 21 rifampin-resistant strains were much higher, ranging from 0.25 to 16.0 micrograms/ml. The MBCs of rifabutine were 0.125 or 0.25 microgram/ml for rifampin-susceptible strains, and were 4.0 and 32.0 micrograms/ml for two tested rifampin-resistant strains. The MIC/MBC ratio was 1:4 for rifampin-susceptible strains.

UI MeSH Term Description Entries
D009169 Mycobacterium tuberculosis A species of gram-positive, aerobic bacteria that produces TUBERCULOSIS in humans, other primates, CATTLE; DOGS; and some other animals which have contact with humans. Growth tends to be in serpentine, cordlike masses in which the bacilli show a parallel orientation. Mycobacterium tuberculosis H37Rv
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D000995 Antitubercular Agents Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy. Anti-Tuberculosis Agent,Anti-Tuberculosis Agents,Anti-Tuberculosis Drug,Anti-Tuberculosis Drugs,Antitubercular Agent,Antitubercular Drug,Tuberculostatic Agent,Tuberculostatic Agents,Antitubercular Drugs,Agent, Anti-Tuberculosis,Agent, Antitubercular,Agent, Tuberculostatic,Anti Tuberculosis Agent,Anti Tuberculosis Agents,Anti Tuberculosis Drug,Anti Tuberculosis Drugs,Drug, Anti-Tuberculosis,Drug, Antitubercular
D012294 Rifamycins A group of ANTI-BACTERIAL AGENTS characterized by a chromophoric naphthohydroquinone group spanned by an aliphatic bridge not previously found in other known ANTI-BACTERIAL AGENTS. They have been isolated from fermentation broths of Streptomyces mediterranei. Rifamycin,Rifomycin,Rifomycins
D017828 Rifabutin A broad-spectrum antibiotic that is being used as prophylaxis against disseminated Mycobacterium avium complex infection in HIV-positive patients. Alfacid,Ansamycin,Ansatipin,Ansatipine,LM-427,Mycobutin,Rifabutine,LM 427,LM427

Related Publications

L B Heifets, and P J Lindholm-Levy, and M D Iseman
[Study of the minimal inhibitory concentration of rifabutine (Ansamycin LM 427) for Mycobacterium tuberculosis, Mycobacterium xenopi and Mycobacterium avium-intracellulare].
January 1988, Revue des maladies respiratoires,
L B Heifets, and P J Lindholm-Levy, and M D Iseman
Minimal bactericidal and inhibitory concentrations of ofloxacin on Mycobacterium fortuitum at pH 7 and 5: therapeutic implications.
September 1990, Tubercle,
L B Heifets, and P J Lindholm-Levy, and M D Iseman
[Defining of gene mutations and minimal inhibitory concentrations in isoniazid resistant Mycobacterium tuberculosis isolates].
October 2017, Mikrobiyoloji bulteni,
L B Heifets, and P J Lindholm-Levy, and M D Iseman
Neuroleptic drugs in the treatment of tuberculosis: Minimal inhibitory concentrations of different phenothiazines against Mycobacterium tuberculosis.
May 2016, Tuberculosis (Edinburgh, Scotland),
L B Heifets, and P J Lindholm-Levy, and M D Iseman
[Bacteriostatic and bactericidal study of rifabutine and clofazimine in combination against Mycobacterium avium-intracellulare and Mycobacterium xenopi].
June 1989, Pathologie-biologie,
L B Heifets, and P J Lindholm-Levy, and M D Iseman
Ranking of QSAR Models to Predict Minimal Inhibitory Concentrations Toward Mycobacterium tuberculosis for a Set of Fluoroquinolones.
September 2010, Acta chimica Slovenica,
L B Heifets, and P J Lindholm-Levy, and M D Iseman
Minimal inhibitory concentrations and minimal bactericidal concentrations of quinupristin/dalfopristin against clinical isolates of Corynebacterium jeikeium and Listeria monocytogenes.
May 1997, The Journal of antimicrobial chemotherapy,
L B Heifets, and P J Lindholm-Levy, and M D Iseman
Minimal inhibitory concentrations of sulbactam/ampicillin against drug sensitive and drug resistant isolates of Mycobacterium tuberculosis.
January 1997, Microbios,
L B Heifets, and P J Lindholm-Levy, and M D Iseman
The minimal inhibitory concentrations of sulphadimethozine and sulphadoxine against Mycobacterium leprae.
October 1970, Leprosy review,
L B Heifets, and P J Lindholm-Levy, and M D Iseman
Isoniazid minimal inhibitory concentrations of tuberculosis strains with katG mutation.
September 2016, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease,
Copied contents to your clipboard!